Alan Yeung, MD

Clinical Focus

• Cardiology (Heart)
• Cardiovascular Disease
• Coronary Artery Disease
• Chronic Total Occlusions
• Complex Coronary Angioplasty

Administrative Appointments

• Chief(Clinical), Division of Cardiovascular Medicine, Stanford University School of Medicine (2000 - present)
• Director, Interventional Cardiology, Stanford University School of Medicine (1998 - present)

Honors and Awards

• Li Ka Shing Professor, Stanford University (2008)

Professional Education

Postdoctoral Advisees

Kaori Nakagawa

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information

Current Research Interests

Coronary artery disease is the leading cause of death in men and women in the United States. Our group is interested in studying both the early and late phases of atherosclerosis so that we can better develop prevention and treatment strategies. Our current studies include:

1) non-invasive methods of assessing vascular endothelial function so that we can better stratefy high risk coronary artery disease patients.

2) structural and functional studies of atherosclerosis in transplant coronary artery disease patients in order to define the the relationship between the two.

3) intravascular ultrasound studies to define the time-course in the devlopment of transplant coronary disease.

4) development of novel techniques to devliver drug imbedded particles into the atherosclerotic wall.

5) study the restenosis process in a vivo pig model.

Clinical Trials

• The PARTNER II Trial with Nested Registries Recruiting
• A Prospective, Single Blind, Randomized Controlled Study to Evaluate the Safety and Effectiveness of the Tryton Side Branch Stent™ used in Conjunction with a Drug-Eluting Stent Compared to Side Branch Balloon Angioplasty in Conjunction with a Drug-Eluting Stent in the Treatment of de novo Bifurcation Lesions Involving the Main Branch and Side Branch within the Native Coronary Circulation Recruiting
• A Prospective, Single Blind, Randomized Controlled Study to Evaluate the Safety and Effectiveness of the Tryton Side Branch Stent™ used in Conjunction with a Drug-Eluting Stent Compared to Side Branch Balloon Angioplasty in Conjunction with a Drug-Eluting Stent in the Treatment of de novo Bifurcation Lesions Involving the Main Branch and Side Branch within the Native Coronary Circulation Recruiting
• SYMPLICITY HTN-3 Recruiting
• Sex Differences in Coronary Pathophysiology Recruiting

Publications

• Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. Yeung AC, Leon MB, Jain A, Tolleson TR, Spriggs DJ, Mc Laurin BT, Popma JJ, Fitzgerald PJ, Cutlip DE, Massaro JM, Mauri L. J Am Coll Cardiol. 2011; 57 (17): 1778-83
• Images in intervention. Intramural hematoma appearing as a new lesion after coronary stenting. Tremmel JA, Koizumi T, O'Loughlin A, Yeung AC. JACC Cardiovasc Interv. 2011; 4 (1): 129-30
• Impact of donor-transmitted atherosclerosis on early cardiac allograft vasculopathy: new findings by three-dimensional intravascular ultrasound analysis. Yamasaki M, Sakurai R, Hirohata A, Honda Y, Bonneau HN, Luikart H, Yock PG, Fitzgerald PJ, Yeung AC, Valantine HA, Fearon WF. Transplantation. 2011; 91 (12): 1406-11
• Comparison of vascular response to zotarolimus-eluting stent vs paclitaxel-eluting stent implantation: pooled IVUS results from the ZoMaxx I and II trials. Waseda K, Hasegawa T, Ako J, Honda Y, Grube E, Whitbourn R, Ormiston J, O'Shaughnessy CD, Henry TD, Overlie P, Schwartz LB, Sudhir K, Chevalier B, Gray WA, Yeung AC, Fitzgerald PJ. Circ J. 2010; 74 (11): 2334-9
• Impact of C-reactive protein on in-stent restenosis: a meta-analysis. Li JJ, Ren Y, Chen KJ, Yeung AC, Xu B, Ruan XM, Yang YJ, Chen JL, Gao RL. Tex Heart Inst J. 2010; 37 (1): 49-57